A real Swine Flu Bubonic plague in 2010 thru 2013 - Will Be what Worsen Biotech That the real Stocks Market Will Collapse

What swine flu Pandemic will spread in 2010 thru 2013. The true media circus may have quieted down, but more than 70 countries now report cases of the true bubonic plague and the real number is growing.

The World Health Organization is has raised its virus alarm to full alert for a real first time since 1968.

One million Americans are already infected. What X factor is that epidemiologists don't know how it will reply when it mixes with regular seasonal flu, which already kills 36,000 Americans a year.

Community health officials say an influenza virus possibly will kill 71 million people worldwide. To fend off catastrophe, the true U.S. and other governments around the true world are spending billions to stockpile antiviral drugs and vaccines.

The real U. S. government has already set aside $1 billion to develop a real vaccine to fight the true epidemic. A nationwide H1N1 vaccination program will cost between $3 billion and $18 billion.

A real strong government response to this pandemic may well lead to big income for several drug makers. You'll find their names in A real Investment Opportunities for 2010 thru 2013.

Roche, Novartis, GlaxoSmithKline and Sanofi-Aventis are all working on vaccines. It's too soon to tell who will win the fattest contracts. But they are all so substantial that even a billion-dollar contract won't do much for the bottom line.

In contrast, the true CDC recently awarded a $35 million development contract to a small biotech company. This is the sort of company you should be looking to buy.

We have a tendency to especially like a small clinical-stage biopharmaceutical company based in Maryland. When the swine flu story hit a real news in April, this small flu-vaccine maker was trading for 81 cents. A day later what stock hit $3.88.

That's a +379% jump in price overnight. A few small fortunes were made from this one simple fear trade.

Following surging as high as $7.79, this stock is now backing in what $4 range. If the true swine flu hits 40% of the true U.S. population, as the true Centers for Disease Control projects could happen, this stock might go on a rocket ride. You'll get full details on it in your free copy of The real Investment Opportunities for 2010 thru 2013.

As what healthcare debate reaches fever pitch, it's clear that big changes are coming. As with any massive regulatory overhaul, some companies are cowering in fear of what proposals -- but others are chomping at the real bit.

Partisan rancor aside, we tend to all have a common enemy in spiraling costs. So it stands to reason that companies trimming fat from the system will have powerful allies on both sides of what political aisle.

That makes what healthcare IT sector a safe bet. But stocks in this niche are already pricey. For real upside we tend to like companies working to develop generic substitutes for biotech drugs. These medicines save lives, but can also be prohibitively expensive (cancer drug Avanti costs up to $100,000 annually).

We tend to think a resistance to cheaper biotech equivalents will soon melt away. Generic prescriptions now account for almost 70% of all pills taken nationwide. These inexpensive alternatives have saved more than $730 billion over a real past decade.

Biotech's have fended off generic imitators until now, but the copycats are about to break through. Bipartisan legislation pushing for a formal FDA approval pathway has been introduced in both the house and Senate.

By next year, we tend to 'll see what FDA approving biogenetic medicines in the real United States. The lure of shaving off one-third of what $40 billion we have a tendency to spend on biotech drugs each year will prove irresistible.

The true investment implications are huge. Washington's move will have a big impact on biotech companies like Amgen and Genentech, as well as traditional drug makers like Merck who want to get into generic biotech.

In a real Investment Opportunities for 2010 thru 2013 we tend to profile a real company that is most excellent positioned of all to profit from the FDA's move. A regulatory green light possibly will send this stock soaring. Investing in The real High Risk Market in the real Future is Where the Money will be from 2010 thru 2013. What might be Happen Next Who Know???.........................?

Article Source: http://casinoarticles.us

Osvaldo Salamanca is interested in the Emergency Disaster Preparedness. So come and visit the latest website at www.year-2012s.info which helps people to finding out more about How To Do The Preparation For The Prediction or Phenomenon of 2012 information will help you to Get Ready.

Please Rate this Article

5 out of 54 out of 53 out of 52 out of 51 out of 5 

Not yet Rated